Adaptimmune Therapeutics plc

ADAPY

US00653A1079

Pharmaceuticals

Delayed OTC Markets Other stock markets 09:43:04 2026-06-18 EDT			5-day change	1st Jan Change
0.0380 ^USD	-5.00%		+31.58%	+53.85%

05-18	Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-17	Adaptimmune Therapeutics plc Announces CEO Changes	CI

Top Midday Decliners

Published on 10/20/2025 at 12:22 pm EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Adaptimmune Therapeutics plc

05-18	Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-17	Adaptimmune Therapeutics plc Announces CEO Changes	CI
11-17	Adaptimmune Therapeutics plc Announces Leadership Changes	CI
25-10-27	Evaxion Names Helen Tayton-Martin as Chief Executive Officer	MT
25-10-26	Adaptimmune Therapeutics plc(OTCPK:ADAP.Y) dropped from NASDAQ Composite Index	CI
25-10-24	European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading	MT
25-10-23	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
25-10-22	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
25-10-21	European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading	MT
25-10-20	Top Midday Decliners	MT
25-10-20	European Equities Close Mostly Higher in Monday Trading; UK Sentiment Sees 'Some of the Gloom Lift'	MT
25-10-20	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
25-10-20	Adaptimmune Therapeutics to Voluntarily Delist From Nasdaq	MT
25-10-17	European Equities Traded in the US as American Depositary Receipts Down in Friday Trading, Up for Week	MT
25-10-16	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT

Chart Adaptimmune Therapeutics plc

Duration

Period

ADAPY: Dynamic Chart

Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.

Employees

506

Sector

Pharmaceuticals

More about the company